AstraZeneca sales jump despite troubles in China
Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It also cited annual budget caps at Chinese hospitals.
Lord Storey says he fears Merseyside was "not a high priority" on the government's growth agenda.
Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...
The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.
Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...
(Reuters) -Strong results from AstraZeneca helped London's blue-chip index notch a record close on Thursday, while a dovish ...
Euronews (English) on MSN23h
AstraZeneca reports strong results boosted by promising trialsAstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
GlobalData on MSN20h
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trialResearchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
Q4 2024 Earnings Call Feb 06, 2025, 6:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants ...
Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback